Analysis of sleep status and impact factor of patients in clinical trials of antineoplastic drugs
10.3760/cma.j.cn211501-20231228-01427
- VernacularTitle:抗肿瘤药物临床试验患者的睡眠现状及影响因素分析
- Author:
Lingjun LI
1
;
Weiying ZHANG
;
Wenjin WANG
;
Xiuyue YANG
;
Yuting HU
;
Jing WANG
;
Xinlu YAN
Author Information
1. 同济大学附属东方医院肿瘤科，上海 200123
- Keywords:
Oncology;
Trial drugs;
Sleep;
Pittsburgh sleep quality index;
Anxiety;
Depression
- From:
Chinese Journal of Practical Nursing
2024;40(29):2279-2284
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the sleep status and impact factor analysis of patients in clinical trials of antineoplastic drugs, and provide a basis for improving the sleep status and impact analysis of patients in clinical trials of antineoplastic drugs.Methods:From April to May 2023, 107 oncology patients in the Phase I Clinical Trial Ward of the Affiliated East Hospital of Tongji University were selected as the research objects by convenient sampling method. The general information questionnaire, Pittsburgh Sleep Quality Index Scale (PSQI), Numeric rating scale (NRS), Generalized Anxiety Disorder Scale (GAD-7) and Depression Self-Ration Tool Scale (PHQ-9). Multivariate Logistic regression analysis methods were used to carry out a cross-sectional investigation and the relevant factors affecting patients′sleep.Results:Totally 103 questionnaires were effectively collected. The 103 patients′ age ranged from 20 to 75 years old, including 61 males and 42 females. 47.57% (49/103) patients in clinical trials of antineoplastic drugs had abnormal sleep. The average score of patients (PSQI) (7.66 ± 3.93) was higher than the average score of the domestic norm (3.88 ± 2.52), and there was significant statistical difference ( t = 9.76, P<0.01). Logistic regression analysis showed that pain ( OR = 3.004, 95% CI 1.135-7.948, P<0.05) and trial cycle ( OR = 0.432, 95% CI 0.191-0.978, P<0.05) were significant risk factors for abnormal sleep quality. Conclusions:The incidence of abnormal sleep quality in patients of clinical trials of antineoplastic drugs is high, but the sleep quality is poor. The factors that affect the sleep quality of patients in clinical trials of antineoplastic drugs are mainly related to the patient′s trial cycle and cancer pain. According to these characteristics, individualized programs should be developed to improve the sleep quality of patients with advanced cancer, so as to improve the quality of life of patients with advanced cancer.
